Greetings. Welcome to I-Mab Biopharma's first half 2024 financial results and corporate update conference call. This time, all participants are in listen-only mode. The question and answer session will follow the formal presentation. If you'd like to ask a question, please press star one on your telephone keypad, and a confirmation tone will indicate your line is in the question queue. You may press star two if you'd like to withdraw your question from the queue. For participants that are using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Also, if anyone should require operator assistance during the conference, please press star zero from your telephone keypad. Please note that this conference is being recorded. I'll now hand the call over to Tyler Enderle, Vice President of Investor Relations. Tyler, you may now begin your presentation. Thank you, operator, and welcome everyone to I-Mab Biopharma's first half 2024 financial results and corporate update conference call. This morning, I-Mab issued a press release reporting its first half 2024 financial results and corporate update. To access a copy of the press release, please visit the investor relations page of the company's website. Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995, which involves risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made, as the underlying facts and circumstances may change. Except as required by law, I-Mab undertakes no obligation to update these forward-looking statements to reflect future information, events, or circumstances. This presentation includes statistical and other industry and market data that we obtain from industry publications and research, surveys, and studies conducted by third parties, as well as our own estimates of potential market opportunities. All of the market data used in this presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. For more information on forward-looking statements, please review the disclaimers in today's press release and the risk factors in the company's SEC filings. With that, I will now turn the call over to Dr. Sean Fu, I-Mab's Interim Chief Executive Officer and Board Director. Thanks, Tyler, and thanks to everyone to join us today. So far this year, 2024, has been transformational for I-Mab. Thanks to the excellent contributions by everyone in our organization. We are executing on the board's vision and delivering on our strategic plan. I'm excited about our continued progress, as demonstrated by significant corporate and pipeline developments. For this morning's call, I will make a few opening remarks regarding our strategic milestones, organization, and pipeline. After that, Dr. Phillip Dennis, our Chief Medical Officer, will provide an update on our three differentiated immuno-oncology therapeutic programs with upcoming milestones. And next, Joseph Skelton, our Chief Financial Officer, will run through a few key financial items, including a review of our cash balance and runway. I'll wrap up with a few closing remarks, then we'll open the call for questions. I joined I-Mab as a board director and interim CEO about a month ago. As I become more familiar with the organization, I'm more enthusiastic about I-Mab and all the team has accomplished so far this year. Furthermore, I believe the combination of our differentiated pipeline, experienced leadership team, and strong cash position will allow us to make meaningful progress in the second half of 2024 and beyond. I'd like to share some of our notable accomplishments from the first half of this year. First was the divestiture of operations in China, announced earlier this year. On April the second, we established a new operating model as a U.S.-based global biotech company. As part of the transaction, we also extinguished $183 million of a redemption obligation. Subsequent to the second quarter, we extinguished an additional $17 million of the redemption obligation. We have efficiently worked to streamline our organization and to build a new US-based leadership team, which includes the addition of Joe as CFO and Philip as CMO. From a corporate governance perspective, we successfully transitioned to having PwC US as our corporate auditor. As you will hear from Philip, we have significantly advanced our three oncology programs. We are squarely focused on execution and believe we are well positioned to make additional progress through the end of this year and beyond. As we look forward, we continue to think strategically and with an open mind to evaluate the new opportunities that could further enhance our pipeline. Moving to slide five. Establishing an experienced US-based management team is critical to I-Mab's long-term success. Our diverse leadership team has experiences in many areas, including conceiving and implementing strategic plans for asset development, deep scientific know-how in developing early-stage targeted therapies for cancer, with a focus on immuno-oncology, identifying and completing strategic transactions, raising capitals, and building successful organizations. In my experience, these are some of the core competencies for successful BioPharma companies today. Our leadership team exemplifies these core competencies. Our collective professional experiences and stellar track records is one of I-Mab's most important strategic competitive advantage. I'm pleased to introduce you to the I-Mab leadership team, including our new CMO, Philip Dennis. Phillip is a renowned lung cancer expert with broad clinical development expertise across a range of therapeutic modalities, with over ten years of a big pharma focus on immuno-oncology, antibody conjugates, and targeted therapies. Our CFO, Joe Skelton, is an experienced investment banker with a track record of successfully executing numerous transactions for biotech and biopharma companies throughout his career. Our Vice President of Clinical Development, Claire Xu, brings significant clinical execution experience running oncology clinical trials and has been a core part of I-Mab's historical U.S. operations, having been at I-Mab for almost seven years. I'm impressed by the team's deep understanding of our clinical programs and their sincere dedication to strategically advancing our pipeline in the best way possible. Moving to slide six. Our pipeline includes three oncology programs focused on providing meaningful therapeutic options to cancer patients with significant unmet medical needs. All of these assets are commercially attractive, supported by co-development and clinical supply agreements with Bristol Myers Squibb, TJ Biopharma, and ABL Bio. Our lead program, Uliledlimab, is an antibody that targets CD73. We're developing it for the treatment of metastatic non-small cell lung cancer and expect to initiate a frontline combination study in the first half of 2025. Meanwhile, TJ Biopharma, our collaborator, expects to read out randomized phase 2 PFS data, combining Uli and Toripalimab in the second half of 2025. Our second program, Givastomig, is a bispecific antibody that targets Claudin 18.2-positive tumor cells, which conditionally activates T cells via 4-1BB, where Claudin 18.2 is expressed. We are developing Givastomig for the treatment of first-line gastric cancers as an add-on to the current standard of care. We expected to present updated data from our phase 1 monotherapy dose expansion study at the European Society for Medical Oncology, or ESMO, 2024 meeting in September. Our third program, Ragistomig, is a bispecific antibody designed to provide anti-PD-L1 and a 4-1BB-driven T-cell activation. It has been developed for cancers that are relapsed or refractory to checkpoint inhibitors and recently presented a compelling early data at ASCO 2024. I'm optimistic about our portfolio. With our early clinical data, our innovative clinical trial strategies, and with a strong team driving these programs forward, offer us the potential to achieve important clinical milestones over the next year and beyond. With that, I would like to turn the call over to Dr. Philip Dennis, I-Mab's Chief Medical Officer. Philip? Thank you, Sean, and good morning, everyone. Over the next few minutes, I will review the recent progress and upcoming milestones of our clinical pipeline, starting with Uliledlimab, or Uli for short. Slide seven begins a section on Uli. Uli targets CD73, which is the rate-limiting enzyme, critical for converting AMP, or adenosine monophosphate, into the immunosuppressive metabolite, adenosine. Blocking CD73 allows antitumor immunity to proceed in the tumor microenvironment without the presence of an adenosine-induced immunological fog. We believe Uli is differentiated, given its superior pharmacokinetic properties versus other competitors, as demonstrated by its ability to completely inhibit CD73 activity without the hook effect that has been described for other drugs that target CD73 and may prevent them from achieving maximal inhibition of CD73. The illustrations on slide eight were created to show Uli's mechanism of action and how Uli is differentiated from other CD73 antibodies. CD73 is activated when it is in a closed conformation. We believe that Uli's differentiation comes from its ability to bind to the C terminus of the enzyme to prevent the formation of the closed dimer. CD73 is a butterfly structure. It has two N termini and two C termini. Because one molecule of Uli binds to two adjacent CD73 dimers on the C- terminus, it doesn't exhibit the hook effect. In fact, our preclinical studies show that this approach completely inhibits CD73 in a dose-dependent manner. In contrast, when looking at other compounds such as oleclumab, which binds to the N-terminus of CD73, what can happen is that as concentrations of drug increase, the intermolecular bonds needed to inhibit CD73 activity are harder to form because the antibodies bind to the N-terminal binding sites with single valency. Therefore, intermolecular bonds are not formed as readily at high concentrations as at lower concentrations, and inhibition of CD73 is paradoxically less at higher concentrations than at lower concentrations. This is not observed with Uli in preclinical model systems. During this call, I will walk you through the three studies from the Uli program. The first study is outlined on slide nine. Data from this study, presented at ASCO 2023, show that patients who had high CD73 expression and a PD-L1 TPS score of greater than or equal to 1%, experienced an objective response rate, or ORR, of 63%. Patients with lower levels of CD73 expression had a lower ORR. The ORR in the CD73 high group is higher than that observed in KEYNOTE-042, which tested pembrolizumab monotherapy in the same disease setting and with the same distribution of PD-L1 expression. These data suggest that tumors with high levels of CD73 expression will respond best to Uli. In addition to providing important proof of concept data, this study also shows that the combination was well tolerated. Two-thirds of metastatic non-small cell lung cancer patients have tumors that express PD-L1 in less than 50% of cells. For them, the standard of care is a checkpoint inhibitor, or IO, combined with chemotherapy. On slide 10, we outline the clinical rationale for a combination study that will include Uli plus IO plus chemotherapy. First, the addition of chemotherapy to IO monotherapy has extended the benefit of IO to patients whose tumors express low levels of PD-L1. Second, Uli has a favorable toxicity profile that suggests that the four-drug combination could be tolerated. Third, published data show that chemotherapy can induce CD73 expression, which could increase the likelihood of response to Uli. Ultimately, non-small cell lung cancer is one of the most common and deadly cancer diagnoses globally, and we believe that Uli has the potential to improve upon currently available standard of care, whether that standard of care is IO monotherapy or IO plus chemotherapy. I-Mab has received FDA clearance to proceed with the study of Uli plus pembro plus chemotherapy, and we expect to dose the first patient in the first half of 2025. In the previous slide, we laid out the rationale for the four-drug combination study. This is an important study because we believe it could help define the regulatory path for Uli in the future. We intend to enroll patients who are eligible for first-line treatment of locally advanced or metastatic non-small cell lung cancer. The study is randomized against IO plus chemo standard of care and is designed to evaluate two different Uli dose levels. Importantly, CD73 expression will be assessed retrospectively. The primary endpoint is objective response rate, with standard secondary endpoints of progression-free survival, duration of response, and overall survival, all stratified by PD-L1 expression. This study includes a small dose escalation lead-in with an N equals to six. Dosing is expected to begin in the first half of 2025. Once safety is assessed in the lead-in, patients will be randomized in a two-to-one ratio against standard of care, assessing Uli with two different dose levels. In this slide, we believe it's important to share not only Uli's upcoming milestones, but the adenosine pathway as a whole, given its promise in the immuno-oncology space. We have prepared this chart to put the upcoming clinical milestones for Uli into context with other CD73 programs. On the top of the chart, we have summarized three milestones for the ongoing and planned studies in our program, including the first patient dosed in the randomized phase 2 study of Uli plus pembro plus chemo I just described. We expect to be able to provide a readout from this study in the second half of 2026. Additionally, we highlight upcoming progression-free survival, or PFS, data from the Uli plus toripalimab randomized phase 2 study ongoing in China only in the second half of 2025. This study is being conducted by our collaborator in China, TJ Biopharma, who holds the right to Uli in China. On the bottom of the chart, we summarize expected phase I, II milestones for four other CD73 programs. We believe that positive results from other programs will help further validate the adenosine pathway, specifically CD73 as a target, and that our approach for patient selection using CD73 expression, as well as Uli's ability to completely inhibit CD73, could represent a differentiated advantage. Next, I'd like to turn to Givastomig on slide 13. Givastomig, or Jeva, is a bispecific antibody that is designed to target claudin 18.2, a tumor-associated antigen found in solid tumors, especially gastric cancers. The bispecific antibody combines the claudin 18.2 binding domain, where claudin 18.2 is expressed, and 4-1BB, which conditionally activates T cells in the tumor microenvironment. Moreover, we believe Jeva is differentiated by its ability to bind to claudin 18.2, even in tumors with very low levels of 18.2 expression. Slide 14 provides an opportunity to highlight Jeva's bispecific design properties and the monotherapy data that may position it as a best-in-class claudin 18.2, 4-1BB bispecific antibody. Initial phase I monotherapy data reported at the ESMO 2023 meeting showed encouraging monotherapy results in patients with gastric cancers whose tumors have progressed or were refractory, including those with low levels of claudin 18.2 expression. Based on the data from the phase I monotherapy results, we initiated a combination study of Jeva, plus Nivolumab, plus chemotherapy in the first half of 2024. Bristol Myers Squibb is supplying Nivolumab under a clinical collaboration and supply agreement. Top-line data from the study are expected to read out in the second half of 2025. In the meantime, I-Mab plans to present new top-line data from the phase I monotherapy dose expansion study in patients with gastric cancers whose disease has progressed after previous treatment at ESMO 2024. Moving to slide 15, investors often ask about other Claudin 18.2 programs in development and how Jeva compares to Zolbetuximab or ZOLBI. In response, we have prepared this comparative slide. On the left side of the chart, we have summarized several parameters from the Jeva phase I monotherapy data presented at ESMO 2023, related to Claudin 18.2 expression and clinical outcomes. On the right-hand columns, we summarize published phase I data and phase II data from Zolbi. While the table does not represent data from a head-to-head study, I believe it highlights the strength and potential differentiation of Jeva. This data highlights Jeva's ability to treat patients even with low levels of claudin eighteen point two expression. For example, ZOLBI did not show a response in its phase I study when claudin eighteen point two was expressed at 1+ or greater than at least 1% of cells. When claudin 18.2 parameters were tightened to 2+ or greater staining in 50% of cells, ZOLBI monotherapy results appeared inferior to Jeva monotherapy results. These data support our view that Jeva has best-in-class potential and could be combined with frontline standard of care, nivo plus chemo, and gastric cancer. Lastly, I'd like to turn to Ragistomig on slide 16. Ragistomig, or Raji, is a bispecific antibody in development to treat advanced solid tumors that are refractory to checkpoint inhibitors. The bispecific antibody was designed to provide anti-PD-L1 activity and four-one BB-driven T cell activation in a single molecule using the same four-one BB technology design as Jeva. The combination of an Fc- silent antibody with conditional 4-1 BB engagement is intended to optimize the compound for safety, including the potential for lower hepatotoxicity compared to traditional four-one BB agonists. Localized activation of four-one BB in the tumor microenvironment is intended to enhance antitumor immunity and reinvigorate exhausted T cells while mitigating liver toxicity and systemic immune responses. Slide seventeen provides a snapshot of early phase I dose escalation and dose expansion data presented at ASCO 2024 by our collaborator, ABL Bio. The study enrolled 53 patients with advanced or relapsed solid tumors, 44 of whom were evaluable at the time of the presentation. The majority of patients had at least three prior lines of treatment. Top line phase I results demonstrated an ORR of 27%, including six partial responses, one complete response, and a clinical benefit ratio of 69%.71% of patients who responded had received prior checkpoint inhibitors. The complete response was observed in a heavily pretreated ovarian cancer patient who had received seven prior lines of therapy. We are encouraged by the results from the study because of the early clinical signs of efficacy. Enrollment in selected indications and different dose schedules is ongoing. Slide 18 provides a snapshot of the safety profile. While increased liver enzymes were the most common treatment-emergent adverse event, none of the transaminase elevations were accompanied by increases in bilirubin, the so-called Hy's Law. Patients with grade three increases in liver enzymes improved with corticosteroid treatment, and no cytokine release syndrome was reported. The combination of RAJI's early efficacy and manageable safety profile is encouraging, and enrollment in the phase 1 study continues. Slide 19 provides a recap of the pipeline. In summary, we are encouraged by the early clinical data for ULI, Jeva, and RAJI. We believe that each agent has a unique and differentiated mechanism of action and a manageable safety profile. We are excited to be on the cusp of clinical milestones for each program, including an upcoming data release at ESMO 2024, where we will share phase 1 dose expansion monotherapy data. Now I will hand the call over to Joe for the financial overview. Thank you, Philip. As we turn to slide 20, we are shifting the discussion to corporate development and finance. As we begin, I want to make a note that we are reporting all of our financial results in U.S. dollars. As we begin to talk about the financials, I want to echo Sean's opening comments that IMAB has executed on the board's vision and made significant strategic and corporate development progress in 2024. I'll touch briefly on 5 key corporate parameters that we believe are strategically important for IMAB. First, we extinguished $200 million of a $215 million redemption obligation. $183 million was extinguished at the time of the divestiture, with another $17 million extinguished subsequent to the end of the second quarter. We expect to extinguish the remaining obligations of approximately $15 million in September of this year. Second, we streamlined the pipeline. We are advancing ULI into phase II in the U.S. and are continuing to advance Jeva through the ongoing phase I-B. With the divestiture of the China operations, two phase III trials shifted to TJ Biopharma, Felzartamab and Eftansomatropin alfa. Third, we strengthened the Jeva clinical program through a clinical trial, collaboration, and supply agreement with Bristol Myers Squibb. BMS is supplying Nivolumab for the triple combination study, evaluating Givastomig in combination with chemotherapy and Nivolumab, the standard of care in frontline gastric cancer. Fourth, we optimized the workforce by streamlining from 220 FTEs at year-end to 34 at June thirtieth. We've also shifted the organization so that the full senior leadership team is based in the U.S. and the workforce is primarily based in the U.S. And lastly, we engaged U.S. auditors. Earlier this month, we announced that we had appointed PwC US as our financial auditors. As we move to slide 21, I would like to take you through a pro forma cash walk using our last reported cash balance and review our cash runway expectations. Starting with our cash walk on slide 21 and moving from left to right, you can see our last reported cash balance as of December 31, 2023, was $321.8 million. And as of June 30, IMAB's reported cash balance was $207.5 million. The delta of $114.3 million is comprised of cash outflows across five major buckets, partially offset by inflows in the second quarter. Item A, $10.8 million of the cash reported at December 31, 2023, remained with the divested I-Mab Shanghai entity to settle working capital obligations, and consistent with ASC 205-20 accounting treatment, was recast to discontinued operations, bringing the comparative year-end cash balance to $311 million. Item B. In the first quarter of 2024, $47.8 million in outflows were incurred related to the divestiture of China operations, including $19 million for our Series C investment in TJ Biopharma. $17.5 million placed into escrow related to arbitration with a dissenting shareholder, which has been subsequently settled. Foreign exchange losses incurred on the transfer of renminbi to US dollars and other non-recurring expenditures associated with the divestiture. Item C. During the first quarter, there were $47.1 million in consolidated operating expenses of the IMAB group pre-closing of the divestiture. Item D. In the second quarter, there were $1.6 million in additional non-recurring expenses incurred associated with the divestiture. Item E. In the second quarter, there were $12.1 million in operating expenses of IMAB as a standalone entity. Of note, there were also cash inflows of $5.1 million, attributable to the return of a deposit to support the share buyback program, which the company no longer anticipates renewing, and interest income earned during the second quarter of 2024. Looking ahead, we believe that based on our current operating plans, our cash runway will take us into 2027, including several important clinical milestones. Moving to slide 22, we have provided a summary of selected financial information and upcoming milestones. To recap on the financials, our cash and cash equivalents and short-term investments were $207.5 million as of June thirtieth, 2024. We believe, based on our current operating plans, that our cash runway will take us into 2027, including several clinical milestones. Our issued and outstanding ordinary shares represent an equivalent of 81.4 million ADSs. Now, I'd like to turn the call back to Sean to wrap up. Thank you, Joe. As we get ready to take your questions, I'd like to summarize the company's upcoming milestones and make a few closing comments. First, we've mapped out four upcoming milestones, two each for Jeva and Uli. For Jeva, we expected to present updated phase one dose expansion data at the ESMO 2024 meeting, and we expected to provide top-line data from the Jeva combo study in gastric cancers in the second half of 2025. For Uli, we expected to initiate the first patient dosed in the combination study in patients with advanced non-small cell lung cancer in the first half of 2025. And we expected to provide top-line progression-free survival data from the randomized phase II study conducted by our collaborator, TJ Bio, in the second half of twenty twenty-five. As we conclude today's prepared remarks, I'd like to leave you with these key messages. I-Mab is exclusively focused on the development of differentiated immunotherapies for cancer. 2024 has been transformational for I-Mab, with the divestiture of operations in China announced on April second. We established a new operating model as a U.S.-based global biotech company. Thanks to the excellent contributions by everyone in our organization, we are executing on the board's strategic vision. We have significantly advanced our three oncology programs and worked efficiently to streamline our organization, build a new U.S.-based leadership team, and have completed key governance and corporate development milestones. As we look forward, we will continue to think strategically to evaluate the new opportunities to further enhance our pipeline. We are squarely focused on execution, and we believe a combination of our differentiated pipeline, experienced leadership team, and strong cash balance position will lead us to make meaningful progress in the second half of 2024 and beyond. Now, I would like to thank everyone for listening to our call and ask the operator to please open the call for questions. Thank you. We'll now be conducting a question and answer session. If you'd like to ask a question at this time, you may press star one from your telephone keypad, and a confirmation tone will indicate your line is in the question queue. You may press star two if you'd like to withdraw your question from the queue. For participants that are using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please, while we pull for questions, and once again, that's star one. Thank you. Thank you. Our first question will be coming from the line of Joe Catanzaro with Piper Sandler. Please proceed with your question. Hey, everybody. Thanks for taking my questions. Maybe I had a couple on Givastomig. First one on the upcoming ESMO update. Wondering if you could just help sort of set expectations in terms of the data set we'll see, patient numbers, and any new learnings around the monotherapy profile there. And then second question, appreciate the comparison to Zolbetuximab, but wondering if you had any thoughts on how Giva maybe compares to the growing Claudin 18.2 ADC landscape and where it could differentiate versus those programs. Thanks. [crosstalks] I was just going to say, we'll turn that question over to our Chief Medical Officer, Dr. Philip Dennis. Thanks, Tyler, and thanks for the question. The data presented at ESMO again will be data from the dose expansion cohorts with gastric cancer. This will be approximately 30 patients. And the profile is again one of exquisite safety and again a notable ORR. But importantly, I think you raised an important question. The way we envision Jeva's development is given its tolerability is to combine it with frontline therapy, with Nivolumab and regimens such as FOLFOX. And I think that's pro-- that is the basis for the differentiation with other 18.2 targeted assets. So while we know that ADCs-... Given their toxic payload, can have a notable objective response rate, which again, if we compared Jeva against the ADC that is being developed by AstraZeneca, our ORR is inferior, but arguably our tox profile is much better suited for combination and frontline studies and I think that's the differentiating feature. I think for an ADC targeting eighteen point two, to move into frontline therapy, one would have to make accommodations in the standard of care chemotherapy, because it simply will be very difficult to tolerate an ADC plus every drug that's in FOLFOX, for example, so I think that's a differentiating feature where we can be more readily combined with frontline therapy. Okay, great. That's all, helpful. Thanks for taking my questions. Our next question has come from the line of Kelly Shi with Jefferies. Please proceed with your question. Hi, this is Hanfei Su for Kelly Shi. Congrats on the progress in the first half of 2024. I just have two quick questions. First, what is your target finish date for the transitioning to the U.S.-based auditors? What should we think about expenses going forward, split between U.S. and China? The second question is for the pipeline strategy. As you're thinking about expansion to your pipeline, adding more assets to your pipeline, are you still focusing on oncology space or looking to expand to other therapeutic areas? Thank you. Thank you for your question, Kelly. Was it possible to repeat the first question, and we'll turn the question over to Sean, our Interim CEO, to answer? Sure. The first question is, what's your target finish date regarding the fully transitioning to a U.S.-based auditor? Yeah, thanks for that question. We have completed the transition, and PwC US is now our corporate auditor, and we've been working closely with them since the completion of the transition. So this is an important accomplishment. And together with other corporate developments after the divestiture, you can start to see the change in, as a company, how I-Mab is allocating resources. The going burn rate, I think that's part of the question you asked earlier. The going burn rate will be considerably lower compared to what you saw in the first and second quarter of this year. Because we have streamlined our organization, we focus on clinical development programs going forward. And the other question you asked about the pipeline strategy. Yes, we are actively looking to further enhance our pipelines through external collaboration or licensing opportunities. Obviously, given that the three assets internally are all oncology-focused, our team has significant oncology asset development experience that we are starting our reviews, our explorations in the oncology space. We are not limiting ourselves just to oncology. For adjacent modalities, we are also open for discussion and collaboration, but oncology is one area we obviously see synergy. I think the final part of your question has to do with going forward with the pipeline strategy. We are squarely focused on execution of our internal pipeline, the three that we explained in detail today by Philip. We're excited about these pipelines, so we're looking to license in, and then we're looking for collaboration opportunities from external partners. Important to know that when we think about the BD strategy, we are looking for assets that has the potential to enter or already in clinical stage. Therefore, we can expect it to bring a near-term value inflection for I-Mab in the next year. Great. Thank you. Thank you. As a reminder, if you'd like to ask a question, you may press star one from your telephone keypad. Our next question is from the line of Andres Maldonado with H.C. Wainwright. Please proceed with your question. Hi, and thank you. Congratulations on the progress. Thank you for taking my question. Just two quick ones from me. For I-Mab combination study, could you talk a little bit about, you know, what you need to see on the efficacy front for this new study? And what are some of the external signals you're using to benchmark your go/no-go decisions? And then, as an additive question, in the second half, the phase II PFS data from the TJ Biopharma study, just curious on, you know, how are you going to leverage that data moving forward and what you need to see there. Thank you very much for taking my question. Thank you for your question, Andres. I will direct your question to our Chief Medical Officer, Dr. Philip Dennis. Oh, thanks. I will address the questions in order, and if I don't do so completely, please. I'll make sure to address all of them. In terms of benchmarks for efficacy in our phase II, the sense is that the comparison is KEYNOTE-189, where we know the median PFS is about nine months, and we know the ORR can vary depending on the PD-L1 expression. So basically, what we're looking for is clinically meaningful improvements, incremental improvements that are clinically meaningful over the standard of care, KEYNOTE-189. Moreover, in our proposed phase II, we'll be assessing CD73 retrospectively, and we will be focused heavily on whether or not the signals that we are seeing are predominantly in that CD73 positive group. Now, in terms of external benchmarks, as the slide showed, we're very interested in outcomes from competitor studies because positive outcomes from these competitor studies will really validate the adenosine pathway, and these studies include studies with Oleclumab that is being developed by AstraZeneca in earlier stages of disease, resectable disease, stage three unresectable disease, excuse me, as well as antibodies against CD39 and small molecules. We think that this will help, again, propel the field forward, give us confidence in Uli, in the pathway. And I think with the signal that we hope to see from our study, from our proposed study with pembro chemo and with the TJ Bio doublet study that is in a CD73-selected population, we will get support for our hypothesis that it's the patients that have high CD73 expression that benefit most from Uli. Great. Thank you very much. Thank you. At this time, there are no additional questions, and I'll hand the call back to Dr. Sean Fu for closing remarks. Great. Thank you very much again for taking the time to join our call today. As you can gather from the discussions and the presentations, we're very excited about the pipeline, and the team is dedicated to continue to push the pipeline forward in the most efficient and scientific way. We look forward to updating you on our future progress. If you have any follow-up questions, please reach out to Tyler Enderle, our Head of Investor Relations. Have a great day. You may now disconnect the call. This will conclude today's conference. Thank you for your participation.